Titre :

Cytogenetic risk score maintains its prognostic significance in aml patients with detectable measurable residual disease undergoing transplantation in remission: on behalf of the alwp/ebmt

Auteur(s) :

Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
CHU Saint-Antoine [AP-HP]
Labopin, Myriam [Auteur]
CEREST-TC [CHU Saint-Antoine]
Canaani, Jonathan [Auteur]
Chaim Sheba Medical Center
Niittyvuopio, Riitta [Auteur]
Helsinki University Hospital [Finland] [HUS]
Socie, Gerard [Auteur]
Hôpital Saint-Louis
Krger, Nicolaus [Auteur]
University Hospital Hamburg-Eppendorf
Itala-Remes, Maija [Auteur]
University of Turku
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Wallet, Helene [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Gallego-Hernanz, Maria Pilar [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Deconinck, Eric [Auteur]
Hôpital JeanMinjoz
Chevallier, Patrice [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Finke, Jurgen [Auteur]
University Hospital Freiburg
Esteve, Jordi [Auteur]
Clinic Barcelona Hospital Universitari
Mohty, Mohamad [Auteur]
CEREST-TC [CHU Saint-Antoine]

Titre de la revue :

American Journal of Hematology

Nom court de la revue :

Am. J. Hematol.

Date de publication :

2020-06-12

ISSN :

1096-8652

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

While evidence for measurable residual disease (MRD) is a harbinger of inferior outcome in acute myeloid leukemia (AML) patients referred for allogeneic stem cell transplantation (allo-SCT), the exact clinical trajectory ...
Lire la suite >While evidence for measurable residual disease (MRD) is a harbinger of inferior outcome in acute myeloid leukemia (AML) patients referred for allogeneic stem cell transplantation (allo-SCT), the exact clinical trajectory of specific patient subsets in this clinical setting is undefined. Using a recently published prognostic cytogenetic model (Canaani et al. Leukemia 2019) we evaluated whether this model applied also to studies of patients with positive MRD. The analysis comprised MRD+wtwt+Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:45:13Z
2024-01-31T13:05:47Z